Midatech raises £10m for gold-nanoparticle delivered insulin and more
This article was originally published in Scrip
Executive Summary
Midatech has raised £10m through a new equity round. The investment was led by Ippon Capital, a Geneva-based VC firm, which committed £7.6m. The remainder came from existing investors. The financing is a quick feather in the cap of new CEO Dr Jim Philips, who joined Midatech in September.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.